Thesis (M.A.)--University of North Carolina at Chapel Hill, 2005. / Includes bibliographical references (leaves 45-51).

Zugl.: München, Univ., Diss., 2008

京都大学 / 0048 / 新制・課程博士 / 博士(医学) / 甲第22310号 / 医博第4551号 / 新制||医||1040(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 渡邉 大, 教授 万代 昌紀, 教授 影山 龍一郎 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Structured summary Aim of the study: To compare the diagnostic reliability, accuracy, and safety of amniocentesis and amniotic fluid Interleukin-6 testing in the diagnosis of intrauterine inflammation of patients with preterm premature rupture of membranes. Type of study: Prospective cohort study Name and location of study site: Department of Gynaecology and Obstetrics, Faculty of Medicine, Charles University in Pilsen Set and methodology: We prospectively examined patients with pPROM between the 23rd and 34th week of gestation in 2014 - 2017. All of them underwent amniocentesis and determination of IL-6 levels in amniotic fluid, leukocytes and bacteria in amniotic fluid as well as maternal blood examination for inflammation parameters. The results were compared to histological examination of the placenta after delivery for the presence of chorioamnionitis. Based on the values mentioned above the sensitivity, specificity, negative and positive predictive value, false positive and negative predictive value and accuracy of the test were determined together with an assessment of statistical significance. Furthermore, the feasibility and incidence of perioperative complications as well as the risk of secondary infection when pregnancy continued were evaluated by serial aniocenteses at weekly intervals. The...

京都大学 / 新制・課程博士 / 博士(医学) / 甲第23468号 / 医博第4775号 / 新制||医||1053(附属図書館) / 京都大学大学院医学研究科医学専攻 / (主査)教授 竹内 理, 教授 山下 潤, 教授 戸口田 淳也 / 学位規則第4条第1項該当 / Doctor of Medical Science / Kyoto University / DFAM

Indiana University-Purdue University Indianapolis (IUPUI) / Chronic inflammation is a major driver of tumor progression in over fifty percent of breast cancers. Tumors activate inflammatory processes by secreting factors that recruit and trigger inflammatory cells to release cytokines such as Interleukin 6 (IL-6). IL-6 stimulates the activity of signal transducers and activators of transcription 3 (STAT3), a transcription factor that has been extensively studied for its role in promoting breast cancer. Recently, downregulated HIPPO signaling was shown to drive the pro-growth effects of IL 6. Reduced HIPPO signaling allows for the nuclear translocation of transcriptional co-activator yes associated protein (YAP), implicating IL-6 in the co-activation of several transcription factors such as the TEADs that trigger pro growth programs. While IL-6/STAT3 stimulation has been shown to increase YAP activity, the mechanism driving this remains undocumented. The Angiomotins (Amots) are adapters of the HIPPO pathway that directly bind and regulate YAP activity. Molecular characterization of Amot transcriptional regulation unexpectedly revealed a single promoter controlling the expression of its two major isoforms: Amot 130 and Amot 80. Through immunofluorescent analysis, this study found that total Amot levels were elevated across multiple breast tumor subtypes and highest in samples with increased presence of stromal inflammatory cells. Further, the induction of total Amot expression by IL 6 was found to be essential for YAP dependent growth of breast cancer cells. The activation of Amot transcription by IL-6 was found to be through Specificity Protein 1 (Sp1), a transcription factor that is activated by STAT3. This work connects the activation of YAP1 by IL-6/STAT3 through the elevation of Amot expression by Sp1. Taken together, this explains a new avenue whereby breast cancer cells acquire enhanced oncogenic properties in response to inflammatory signaling.

Die Nicht-alkoholische Fettlebererkrankung (NAFLD) ist eine der häufigsten chronischen Lebererkrankungen der westlichen Welt. Die Pathogenese der Erkrankung ist noch nicht vollständig erforscht und wirksame medikamentöse Therapien sind bisher nicht zugelassen. Wachsende Evidenz zeigt, dass das Interleukin-6-Typ-Zytokin Oncostatin M (OSM) eine wichtige Rolle in der Pathogenese der NAFLD spielt. Die japanische Arbeitsgruppe um Komori et al. zeigte an OSM-Rezeptor-β-defizienten (Osmr-KO-) Mäusen sowie durch OSM-Behandlung von genetisch und ernährungsbedingt adipösen Mäusen, dass OSM vor einer hepatischen Steatose und metabolischer Komorbidität schützen kann. Andere Publikationen suggerieren, dass OSM an NAFLD-Entwicklung und -Progression beteiligt ist, indem es die Expression von Genen der β-Oxidation und Very-Low-Density-Lipoprotein (VLDL-) Sekretion reprimiert und die Expression profibrogenetischer Gene fördert. Low-Density-Lipoprotein-Rezeptor-defiziente- (Ldlr-KO-) Mäuse sind seit Langem als Atherosklerose-Modell etabliert und wurden zuletzt auch als physiologisches Modell für NAFLD identifiziert. Um die Rolle von OSM in der NAFLD-Pathogenese zu beleuchten, wurden Osmr-KO-Mäuse auf Wildtyp- (WT-) und Ldlr-KO-Hintergrund untersucht, die über 12 Wochen eine fett- und cholesterinreiche Western Diet erhielten und anschließend für die Organentnahme geopfert wurden. Im Vorfeld dieser Arbeit wurden Körpergewicht, Blutglukose, Serum-Cholesterin und Lebergewicht der Tiere gemessen. Hierbei zeigte sich ein erhöhtes Körpergewicht, unveränderte Blutglukose, erhöhtes Serum-Cholesterin sowie ein erhöhtes Lebergewicht in Osmr-KO- gegenüber WT-Mäusen. Andersherum waren Körpergewicht, Blutglukose, Serum-Cholesterin und Lebergewicht in Ldlr-Osmr-KO- gegenüber Ldlr-KO-Mäusen vermindert. Im Rahmen der vorliegenden Arbeit erfolgte die histologische Untersuchung des Lebergewebes, die Messung von Serum-Triglyzeriden und Fettsäuren sowie die Untersuchung der hepatischen Genexpression. An kultivierten Zellen der humanen Hepatom-Zelllinie HepG2 wurde eine mögliche Regulation der CYP7A1-Genexpression durch OSM untersucht. CYP7A1 ist als Schrittmacherenzym der Gallensäuresynthese an der hepatischen Cholesterin-Clearance beteiligt. Osmr-KO-Mäuse zeigten gegenüber WT-Mäusen histologisch eine verstärkte hepatische Steatose. Bei der Untersuchung der mRNA-Expression von Genen mit Beteiligung an der hepatischen Lipidhomöostase zeigte sich eine Minderexpression von Ldlr in Osmr-KO-Mäusen. Weiterhin zeigte sich eine etwas geringere Expression von Cyp7a1 in Osmr-KO-Mäusen. Die Expression aller anderen untersuchten Gene, die an Fettsäuresynthese, Cholesterintransport und –metabolismus beteiligt sind, lieferten keine Erklärung für eine erhöhte hepatische Lipidakkumulation in Osmr-KO-Mäusen. Ldlr-Osmr-KO-Mäuse hatten gegenüber Ldlr-KO-Mäusen eine geringer ausgeprägte hepatische Steatose. Die mRNA-Expression von Genen der Fettsäuresynthese, der Cholesterinbiosynthese und des Cholesterintransports waren in Ldlr-Osmr-KO- gegenüber Ldlr-KO-Mäusen nicht wesentlich verändert. Allerdings fiel eine deutliche Hochregulation von Cyp7a1 in Ldlr-Osmr-KO-Mäusen auf. Darüber hinaus war Osm in Ldlr-KO-Mäusen gegenüber WT-Mäusen stärker exprimiert. Um eine Regulation von CYP7A1 durch OSM nachzuweisen, wurde die Genexpression in HepG2-Zellen nach Stimulation mit OSM untersucht. Hierbei zeigte sich, dass OSM die mRNA-Expression von CYP7A1 supprimierte. Dieser Effekt war durch die Zugabe von Inhibitoren der Januskinasen (JAK), Mitogen Activated Protein Kinase/ERK-Kinase (MEK) und Extracellular-signal Regulated Kinase ½ (ERK1/2) reversibel. Die CYP7A1-Suppression durch OSM ging mit einer verminderten Expression des Transkriptionsfaktor-Gens HNF4A einher. Osmr-KO-Mäuse zeigten gegenüber WT-Mäusen nach 12 Wochen Western Diet verstärkte Adipositas, Dyslipidämie sowie eine hepatische Steatose. Die Analyse der hepatischen mRNA-Expression legt nahe, dass die Minderexpression von Ldlr in Osmr-KO-Mäusen im Vergleich zu WT-Mäusen zur Verstärkung der Dyslipidämie und hepatischen Steatose beigetragen hat. Weiterhin kann die geringere Expression von Cyp7a1 in Osmr-KO-Mäusen durch daraus resultierende Akkumulation von Cholesterin zur erhöhten hepatischen Lipidakkumulation in diesen Mäusen beigetragen haben. Ldlr-KO-Mäuse zeigten nach 12 Wochen Western Diet ebenfalls eine hepatische Steatose. Diese war in Ldlr-Osmr-KO-Mäusen gegenüber Ldlr-KO-Mäusen geringer ausgeprägt. Die erhöhte Expression von Cyp7a1 in Ldlr-Osmr-KO-Mäusen kann die Verbesserung von hepatischer Lipidakkumulation und Dyslipidämie durch erhöhte Cholesterinmetabolisierung zu Gallensäuren erklären. Übereinstimmend mit der Cyp7a1-Regulation in LDLR-defizienten Mäusen zeigte sich in vitro, dass OSM die Expression von CYP7A1 in HepG2-Zellen vermindert und sich so negativ auf die hepatische Lipidhomöostase auswirken kann. Insgesamt implizieren diese Ergebnisse eine divergierende Rolle von OSM bei der Entwicklung einer hepatischen Steatose abhängig vom genetischen Hintergrund. OSM scheint bei WT-Mäusen für die Erhaltung der metabolischen Gesundheit wichtig zu sein. Bei Ldlr-KO-Mäusen hingegen scheint OSM die Entwicklung von Adipositas, Dyslipidämie und hepatischer Steatose zu fördern. Die differenzielle Rolle in WT- und Ldlr-KO-Mäusen könnte durch unterschiedliche Osm-Expressionsspiegel zustande kommen: Während basale OSMRβ-Signaltransduktion durch geringe OSM-Spiegel in WT-Mäusen für die Lipidhomöostase essenziell zu sein scheint, könnte erhöhte oder prolongierte OSMRβ-Signaltransduktion durch höhere OSM-Spiegel in Ldlr-KO-Mäusen das Fortschreiten der hepatischen Steatose fördern. Dies stellt OSM als mögliches NAFLD-Therapeutikum in Frage. Um die Hypothese zu überprüfen, dass OSM abhängig von der Höhe und Kinetik der Spiegel günstige oder ungünstige Effekte auf die NAFLD-Entwicklung hat, sollte in zukünftigen Experimenten der Einfluss kurz- und langfristiger Behandlung von WT-Mäusen mit OSM unterschiedlicher Konzentrationen auf die Entwicklung einer hepatischen Steatose untersucht werden. / Non-alcoholic fatty liver disease (NAFLD) is among the most common chronic liver diseases in Western societies. Pathogenetic mechanisms are not fully elucidated and to date there is no approved drug therapy available. There is mounting evidence that the Interleukin-6-type-cytokine Oncostatin M (OSM) plays a crucial role in the pathogenesis of NAFLD. The Japanese working group of Komori et al. had shown that OSM has favorable effects on metabolism und protects against hepatic steatosis using OSM-receptor-β-deficient (Osmr-KO-) mice as well as OSM treatment of genetically or diet-induced obese mice. Other publications suggest that OSM contributes to the pathogenesis and progression of NAFLD by reducing the expression of genes involved in β-oxidation and Very-Low-Density-Lipoprotein (VLDL) secretion and inducing the expression of genes involved in fibrogenesis. Recently Low-Density-Lipoprotein-Receptor-deficient (Ldlr-KO-) mice, which are a well-established model for atherosclerosis, have also been considered a physiological model for NAFLD. To further investigate the role of OSM in NAFLD pathogenesis Osmr-KO mice on either wild type- (WT-) or Ldlr-KO-background were fed a high-fat and high-cholesterol Western diet for 12 weeks and were then sacrificed for tissue collection. Prior to the present thesis body weight, blood glucose levels, serum cholesterol and liver weight of the mice were measured. Osmr-KO mice showed increased body weight, serum cholesterol levels and liver weight compared to WT mice, whereas blood glucose levels did not differ. On the contrary, Ldlr-Osmr-KO mice showed decreased values in all parameters compared to Ldlr-KO mice, including body weight, blood glucose levels, serum cholesterol levels and liver weight. In the present thesis a histological examination of the liver tissue was made, serum levels of triglycerides and fatty acids were measured, and hepatic gene expression was analyzed. In cultured cells of the human hepatoma cell line HepG2 a potential regulation of CYP7A1 gene expression by OSM was examined. CYP7A1 is the rate limiting enzyme of bile acid synthesis and is therefore involved in hepatic cholesterol clearance. Osmr-KO mice showed enhanced hepatic steatosis compared to WT mice. Examination of gene expression involved in hepatic lipid homeostasis revealed reduced Ldlr expression levels in Osmr-KO mice. Furthermore, a slightly decreased Cyp7a1 expression was observed. The expression of other genes involved in fatty acid synthesis, cholesterol transport and cholesterol metabolism did not explain the enhanced hepatic lipid accumulation in Osmr-KO mice. In Ldlr-Osmr-KO mice hepatic steatosis was reduced compared to Ldlr-KO mice. The expression of genes involved in fatty acid synthesis, cholesterol synthesis and cholesterol transport was not considerably altered in Ldlr-Osmr-KO compared to Ldlr-KO mice. However, Cyp7a1 was markedly upregulated in Ldlr-Osmr-KO mice. In addition, Osm expression was increased in Ldlr-KO mice compared to WT mice. To prove the regulation of CYP7A1 by OSM, gene expression was determined in OSM-treated HepG2 cells. The results show that OSM attenuated CYP7A1 expression. This effect was reversed by the addition of inhibitors of either januskinases (JAK), mitogen-activated protein kinase/ERK-kinase (MEK) or extracellular-signal regulated kinase 1/2 (ERK1/2). CYP7A1-suppression by OSM was accompanied by reduced expression levels of the transcription factor gene HNF4A. After 12 weeks of Western diet Osmr-KO mice showed enhanced obesity, dyslipidemia and hepatic steatosis compared to WT mice. Determination of hepatic gene expression suggests that decreased expression of Ldlr in Osmr-KO mice compared to WT mice contributes to dyslipidemia and hepatic steatosis. Furthermore, the decreased expression of Cyp7a1 in Osmr-KO mice may contribute to cholesterol accumulation and accordingly to hepatic lipid accumulation in these mice. Ldlr-KO mice also showed hepatic steatosis after 12 weeks of Western diet. In comparison, hepatic steatosis was markedly reduced in Ldlr-Osmr-KO mice. Increased expression levels of Cyp7a1 and hence enhanced metabolization of cholesterol to bile acids in Ldlr-Osmr-KO mice can explain improved hepatic lipid accumulation and dyslipidemia in these mice compared to Ldlr-KO mice. Consistent with the discovered Cyp7a1 regulation in LDLR-deficient mice, OSM decreased the expression of CYP7A1 in HepG2 cells and therefore may have detrimental effects on hepatic lipid homeostasis. Altogether the results implicate a diverging role of OSM in the pathogenesis of hepatic steatosis depending on the genetic background. In WT mice OSM seems to convey protective effects on lipid homeostasis, whereas in Ldlr-KO mice OSM seems to promote the development of obesity, dyslipidemia and hepatic steatosis. The differential role of OSM in WT and Ldlr-KO mice might be caused by diverging Osm expression levels: Basal OSMRβ signal transduction caused by low OSM levels seems to be essential for lipid homeostasis, whereas enhanced or prolonged OSMRβ signal transduction caused by higher OSM levels might foster the progression of hepatic steatosis. These findings question OSM as a putative therapeutic agent for NAFLD. To test the hypothesis that OSM has beneficial or detrimental effects on NAFLD pathogenesis depending on OSM levels and kinetics, future studies should examine the effect of short- and long-term administration of OSM in different concentrations on the development of hepatic steatosis in WT mice.

No description available.

<p> Mammalian sialidases are hydrolytic enzymes that initiate the removal of terminal a2-3, a2-6 and a2-8 sialic acid residues from various sialylated glycoconjugates. Sialidases are reportedly involved in numerous cellular functions involving proliferation, differentiation, antigenic expression, inflammation and the tumorigenicity of malignant cells. Recently, sialidase has been implicated in various immune signaling pathways, involving immune effector cells, such as activated lymphocytes and macrophages. The human lysosomal sialidase gene encodes a 46 kD glycoprotein which exists in a multienzyme complex with β-galactosidase and PPCA. Neurodegenerative diseases such as Tay-Sachs and Sandhoff are characterized by the progressive storage of glycoproteins and sialylated oligosaccharides in the nervous system. The induction of inflammatory mediators is a critical step in the pathogenesis of neurodegeneration that remains largely undefined. As such, an in vitro model of Tay-Sachs disease was used to identify potential mediators involved in disease progression. In addition, we have used the THP-1 monocytic cell line as a model of human macrophages which play a key role in potentiating a variety of immune responses. </p> <p> Translocation of neul from lysosomes to the cell surface and the resulting interaction with signaling molecules suggests neul is involved in the regulation of immune activities. We have investigated the role of sialidase on CD44 expression, an inflammation-associated glycoprotein found on the cell surface. Our data indicate that sialidase interacts with CD44 on the cell surface which may contribute to disease progression in Tay-Sachs disease. We illustrate that overexpression of sialidase stimulates interleukin-6 (IL-6) secretion in both human Tay-Sachs neuroglia and THP-1 derived macrophages. Moreover, the sialidase inhibitor 2-deoxy-2, 3-dehydro-N-acetylneuraminic acid (DANA) was found to attenuate IL-6 secretion and sialidase expression in THP-1 derived macrophages. </p> / Thesis / Master of Science (MSc)

Genotype-phenotype analyses continue to be the primary goal for genome analyses in livestock and poultry breeding. Essential to accomplish this goal is the need to identify variation at the genomic level. To test the hypothesis that DNA sequence variations in inflammatory response genes are associated with phenotypic differences in the heritage turkey, the primary objective of this project was to search for single nucleotide polymorphisms (SNPs) in candidate inflammatory response genes. A minor objective was to develop a system for inducing inflammatory response in the turkey using a microbe-based lipopolysaccharide (LPS), an approach previously described for the chicken. A total of 18 SNPs was identified in the three genes screened in this project: Interleukin 6 (IL6) and 8 (IL8), and NLRX1. Mortality data from the LPS challenge were not significantly different among the strains. Further gene expression analyses will be part of future work. The SNP data represent the first extensive analyses of candidate inflammatory response genes in the turkey. Combined with the protocols developed for inflammation assessment in the turkey the SNPs described here will be valuable resources for future inflammation:genotype evaluation in the turkey / MS / Though progress has been made in the genome analyses of the turkey, Meleagris gallopavo, our understanding of the genotype: phenotype relationships continue to lag those of agriculturally important animal species. Among the phenotypes for which genetic understanding can be useful is inflammation, a complex trait that is influence by many interdependent response mechanisms. These mechanisms, regarding differences across heritage turkeys, has been mildly investigated. Since Nucleotide Polymorphism (SNP) screening is a common method used to comprehend the robust effects these differences have on genotype and phenotype. Here, we report initial investigations in our lab of the genetics of inflammation in the turkey using comparative information from the chicken NOD like receptor X1 (NLRX1), turkey interleukin 6 (IL6), and Interleukin 8 (IL8). These genes were screened for nucleotide variants that may be informative for future studies that will investigate the turkey’s response to Salmonella derived lipopolysaccharide that can induce inflammation. The rationale for selecting these three genes is that IL8, IL6, and NLRX1 have pro inflammatory and/or anti-inflammatory functions that respond to maintain homeostasis. Primers were designed and investigated using DNA from Broad Breasted White (BBW), and Broad Breasted Bronze (BBB), Blue slate (SL), Spanish Black (SBL), Midget White (MW) and Royal Palm (RP). The birds were also challenged with 1.5 mg/kg Lipopolysaccharide (LPS) intra-abdominally to collect tissue post LPS challenge. Tissues was collected from the thymus, spleen, and bursa of fabricius: organs identified to effect inflammation. A total of 2,239 bp for IL8, 2,439 bp for IL 6, and 572 bp for NLRX1 were screened for SNPs. SNP analysis revealed 16 SNPs in the inflammatory response genes mentioned.